HomeNewsBusinessEconomyExclusive | FY22 tax revenue targets could be exceeded, says chief economic advisor

Exclusive | FY22 tax revenue targets could be exceeded, says chief economic advisor

Speaking to Moneycontrol, Subramanian said the economic impact of the third wave could be minimal, and that the vaccination programme seemed well on track to inoculate all adults by December-end

September 28, 2021 / 19:09 IST
Story continues below Advertisement

Given the strong recovery in almost all sectors, and the very encouraging tax proceeds so far, the tax revenue targets set in the budget could be exceeded, Chief Economic Advisor Krishnamurthy Subramanian said.

Speaking exclusively to Moneycontrol, Subramanian said that although signs were encouraging and he did see some upside to his 2021-22 gross domestic product growth projection of 11 percent, a possible third wave of the Covid-19 pandemic still remained an unknown factor.

Story continues below Advertisement

“Even with me being conservative and not changing my projections for real growth, nominal growth may actually be higher and tax buoyancy also contribute. So both of those could actually lead to the tax revenues being higher than budgeted,” Subramanian said.

The 2021-22 budget has estimated net tax proceeds of Rs 15.45 lakh crore. Tax proceeds are usually backloaded, as most of it comes in the second half of the year, while expenditure is front-loaded.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show